Nitya Nathwani, M.D.

800-826-4673
Nitya Nathwani, M.D.
Hematologist
Clinical Expertise
Multiple Myeloma
Research Area
Multiple Myeloma
Hematology And Hematopoietic Cell Transplantation
Languages
Hindi
Appointments
Associate Professor, Division Of Myeloma, Department Of Hematology & Hematopoietic Cell Transplantation
Clinical Teams
Hematology & Hematopoietic Cell Transplantation
Myeloma And Multiple Myeloma
“Participating in efforts to advance the care of myeloma patients and working to find a cure for this disease, while simultaneously providing compassionate, personalized patient care based on characteristics ranging from disease biology to frailty assessment, is the ideal blend of academic challenges and personal satisfaction that I seek in my career.”

Nitya Nathwani, M.D., earned his medical degree from Topiwala National Medical College in Mumbai, India, before moving to Southern California, where he completed his internal medicine residency at Los Angeles County+USC Medical Center. He pursued a hematology-oncology fellowship at LAC+USC and the Norris Comprehensive Cancer Center. Dr. Nathwani’s clinical and research interests center on multiple myeloma. He has been the principal investigator at City of Hope for several high-profile clinical trials in multiple myeloma and led a study of older adults with the disease. In addition to being a member of the Judy and Bernard Briskin Center for Multiple Myeloma Research, he is the Medical Director of hematologic malignancies, transplantation, and cellular therapy at AccessHope.

Dr. Nathwani has published several peer-reviewed publications, reviews and book chapters and has been invited to present his work nationally and internationally.

Location
Education & Experience
Degrees

  • 1996-2002, M.B.B.S., Topiwala National Medical College, Mumbai, India

  • 1994-1996, H.S.C., Science, Jai Hind College, Mumbai, India

Fellowship

  • 2011-2012, Bone Marrow Transplant Fellowship, City of Hope, Duarte, CA

  • 2007-2010, Hematology-Oncology Fellowship, LAC+USC Medical Center, Los Angeles, CA

Residency

  • 2004-2007, Internal Medicine Residency, LAC+USC Medical Center, Los Angeles, CA

Internship

  • 2001-2002, Rotating Extern at Methodist Hospitals, Merrillville, IN

Professional Experience

  • 2022-present, Medical Director, Hematologic Malignancies, Transplantation, and Cellular Therapy, AccessHopeTM

  • 2020-present, Associate Professor, Division of Myeloma, Department of Hematology & Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA

  • 2012-2020, Assistant Clinical Professor, Division of Myeloma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA

Research
Lab Members
Dr. Nathwani has been the principal investigator at City of Hope for several high-profile clinical trials in multiple myeloma, including 2 landmark trials involving quadruplet induction therapy that has changed the myeloma treatment landscape, and a trial defining the role of transplant in the US. He led a multi-center study in older adults with the disease. His team performed a tablet-based modified geriatric assessment which influenced treatment decisions, while potentially increasing the safety of myeloma therapy.
Awards & Memberships
Memberships

  • 2020, Clinical Path Multiple Myeloma Medical Oncology Committee

  • 2017, National Comprehensive Cancer Network (NCCN) Cancer in HIV-Positive Patients’ Panel

  • 2017, NCCN AIDS Related Kaposi Sarcoma Panel

  • 2012, Cancer and Aging Research Group

  • 2011, American Society for Blood and Marrow Transplantation

  • 2011, Los Angeles County Medical Association

  • 2008, American Society of Hematology

  • 2007, American Society of Clinical Oncology

  • 2004, American College of Physicians

Publications

  • Slade M, Martin TG, Nathwani N, Fiala MA, Rettig MP, Gao F, Deol A, Buadi FK, Kaufman JL, Hofmeister CC, Gregory TK, Berdeja J, Chari A, Rosko A, Vij R. Ixazomib, lenalidomide and dexamethasone consolidation with randomized ixazomib or lenalidomide maintenance after autologous transplant in newly diagnosed multiple myeloma. Leukemia. 2022 Sep 16;. doi: 10.1038/s41375-022-01691-1. [Epub ahead of print] PubMed PMID: 36114265.

  • P.G. Richardson, S.J. Jacobus, E.A. Weller, H. Hassoun, S. Lonial, N.S. Raje, E. Medvedova, P.L. McCarthy, E.N. Libby, P.M. Voorhees, R.Z. Orlowski, L.D. Anderson, Jr., J.A. Zonder, C.P. Milner, C. Gasparetto, M.E. Agha, A.M. Khan, D.D. Hurd, K. Gowin, R.T. Kamble, S. Jagannath, N. Nathwani, et al. Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. New England Journal of Medicine. 2022. Jul 14;387(2):132-147. doi: 10.1056/NEJMoa2204925. Epub 2022 Jun 5. PMID: 35660812

  • Nathwani N, Bell J, Cherepanov D, Ginchereau Sowell F, Shah R, McCarrier K, Hari P. Patient perspectives on symptoms, health-related quality of life, and treatment experience associated with relapsed/refractory multiple myeloma. Supportive Care in Cancer. 2022 Jul;30(7):5859-5869. doi: 10.1007/s00520-022-06979-7. Epub 2022 Apr 1. PMID: 35364733

  • Nathwani N, Bertamini L, Banjeree R, Gay F, Shah N, Krishnan A. When and How to Treat Relapsed Multiple Myeloma. Am Soc Clin Oncol Educ Book. 2021 Mar;41:358-375. doi: 10.1200/EDBK_320129 PMID: 34010043

  • Voorhees PM, Rodriguez C, Reeves B, Nathwani N, et al. Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone in Patients with Transplant-eligible Newly Diagnosed Multiple Myeloma: Updated Efficacy and Safety Analysis of the Safety Run-in Population of GRIFFIN Blood Adv 2021 Feb 23;5(4):1092-1096. doi: 10.1182/bloodadvances.2020003642. PMID: 33606004

  • Krishnan A, Adhikarla V, Poku E, Palmer J, Chaudhry A, Biglang-awa V, Bowles N, Nathwani N, et al. Identifying CD38+ cells in patients with multiple myeloma: First-in-human imaging using copper-64-labeled daratumumab. Blood Advances 2020 October 27; 4(20):5194-5202 PMID: 33095874
  • Nathwani N, Palmer J, Synold TW, et al. Toxicities associated with metformin/ritonavir combination treatment in relapsed/refractory multiple myeloma.  Clinical Lymphoma Myeloma and Leukemia, 2020 May 29; S2152-2650(20)30263-9. PMID 32631779
  • Voorhees PM, Kaufman JL, Laubach JP, Sborov DW, Reeves B, Rodriguez C, Chari A, Silbermann R, Costa LJ, Anderson LD, Nathwani N, et al. Daratumumab, lenalidomide, bortezomib, & Dexamethasone for transplant-eligible newly diagnosed multiple myeloma: GRIFFIN. Blood. 2020 Apr 23: PMID: 32325490 
  • Nathwani N, et al. Integrating Touchscreen-Based Geriatric Assessment and Frailty Screening for Adults With Multiple Myeloma to Drive Personalized Treatment Decisions.  J Oncol Pract. 2019 Nov 25:JOP1900208. doi: 0.1200/JOP.19.00208. PMID: 3176526
  • Rosenzweig M, Palmer J, Tsai N, Synold T, Wu X, Tao S, Hammond S, Buettner R, Duarte L, Htut M, Karanes C, Nathwani N, et al. Repurposing Leflunomide for Relapsed/Refractory Multiple Myeloma: A Phase 1 Study. Leuk Lymphoma. 2020 Apr 8:1-9. doi: 10.1080/10428194.2020.1742900. PMID: 32268821
  • Hsu T, Nathwani N, Loscalzo M, Hurria A, et al. Understanding Caregiver Quality of Life in Caregivers of Hospitalized Older Adults With Cancer. J Am Geriatr Soc. 2019 May;67(5):978-986. doi: 10.1111/jgs.15841. Epub 2019 Mar 22. PMID:30901083
  • Al Malki M, Nathwani N, et al (co-first author). Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 2018 May 9. PMID 29753158
  • Reid E, Suneja G, Ambinder RF, Ard K, Baiocchi R, Barta SK, Carchman E, Cohen A, Gupta N, Johung KL, Klopp A, LaCasce AS, Lin C, Makarova-Rusher OV, Mehta A, Menon MP, Morgan D, Nathwani N, Noy A et al. Cancer in People Living With HIV, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018 Aug;16(8):986-1017. doi: 10.6004/jnccn.2018.0066. PMID: 30099375
  • Reid E, Suneja G, Ambinder RF, Ard K, Baiocchi R, Barta SK, Carchman E, Cohen A, Crysler OV, Gupta N, Gustafson C, Hall A, Johung KL, Klopp A, LaCasce AS, Lin C, Mehta A, Menon MP, Morgan D, Nathwani N, Noy A, et al.  AIDS-Related Kaposi Sarcoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.J Natl Compr Canc Netw. 2019 Feb;17(2):171-189. doi: 10.6004/jnccn.2019.0008. PMID: 30787130
  • Armenian SH, Mertens L, Slorach C, Venkataraman K, Mascarenhas K, Nathwani N, Wong FL, et al. Prevalence of anthracycline-related cardiac dysfunction in long-term survivors of adult-onset lymphoma. Cancer. 2018 Feb 15;124(4):850-857. doi: 10.1002/cncr.31110. Epub 2017 Nov 7.PMID: 29112235
  • Krishnan A, Kapoor P, Palmer JM, Tsai NC, Kumar S, Lonial S, Htut M, Karanes C, Nathwani N, Rosenzweig M, et al. Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma. Leukemia. 2017 Dec 18.  PMID 29249822
  • Hurria A,  Akiba C, Kim J,  Mitani D, Loscalzo M, Katheria V,  Koczywas M, Pal S, Chung V, Forman S, Nathwani N,  Fakih M, et al. Reliability, Validity, and Feasibility of a Computer Based Geriatric Assessment for Older Adults with Cancer. Journal of Oncology Practice 2016. 2016 Sep 13. pii: JOPR013136. PMID: 27624950
  • Chen R, Frankel P, Popplewell L, Siddiqi T, Ruel N, Rotter A, Thomas SH, Mott M, Nathwani N, Htut M, Nademanee A, Forman SJ, Kirschbaum M. A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma. Haematologica. 2015 Mar;100(3):357-62
  • Li X, Chyu KY, Faria Neto JR, Yano J, Nathwani N, Ferreira C, Dimayuga PC, Cercek B, Kaul S, Shah PK. Differential effects of apolipoprotein A-I–mimetic peptide on evolving and established atherosclerosis in apolipoprotein E-null mice. Circulation 2004; 110(12): 1701-1705.
Ratings & Reviews
Ratings and reviews below are gathered from the Press Ganey Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CG CAHPS) survey. CG CAHPS is a standardized survey that is used to measure a patient's experience in the physician office setting. Ratings are an average of all responses to questions about a provider's care, with 5 stars being the highest.
Ratings
4.9
Know important info medical history
4.9
Show respect for what you say
4.8
Provider explain in way you understand
4.8
Provider listen carefully to you
4.8
Spend enough time with you
4.8
Rate provider 0-10
4.8
Recommend this provider office
Reviews
07/10/22
Dr Nathwani couldn't hear us so he had to call us on the telephone - Verified patient
06/09/22
Good - Verified patient
06/09/22
Good - Verified patient
06/09/22
Good - Verified patient
04/06/22
It has been over [...] working with Dr. Nathwani, a caring responsible doctor, never had any bad experience. Feels like a brother to me and feels like a family. From the start I left my life in Gods hand and the science with him. - Verified patient